Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Filing Date
Feb 4, 2019
Document Date
Feb 4, 2019
Form Description
An amendment to the SC 13G filing
Filing Group
3,4,5
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp